ARQULE
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcrip... tion Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).
ARQULE
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1993-01-01
Address:
Woburn, Massachusetts, United States
Country:
United States
Website Url:
http://www.arqule.com
Total Employee:
11+
Status:
Closed
Contact:
781-994-0300
Email Addresses:
[email protected]
Total Funding:
9.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Domain Not Resolving Nginx Microsoft Exchange Online IPv6 Microsoft Azure DNS Cloudflare JS
Similar Organizations
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
SpeciGen Inc.
SpeciGen is a developmental biotechnology company, engages in the design and development of protein cages that contain samples of cancer.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2003-07-18 | Cyclis Pharmaceuticals | Cyclis Pharmaceuticals acquired by ArQule | 25 M USD |
| 2001-01-22 | Camitro | Camitro acquired by ArQule | 106.2 M USD |
Investors List
Pontifax
Pontifax investment in Post-IPO Equity - ArQule
Atlas Venture
Atlas Venture investment in Seed Round - ArQule
Official Site Inspections
http://www.arqule.com Semrush global rank: 7.73 M Semrush visits lastest month: 437
Unable to get host informations!!!
